S
Sanjiv Chopra
Researcher at Beth Israel Deaconess Medical Center
Publications - 36
Citations - 2162
Sanjiv Chopra is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Cirrhosis & Randomized controlled trial. The author has an hindex of 17, co-authored 36 publications receiving 2036 citations. Previous affiliations of Sanjiv Chopra include Brigham and Women's Hospital & Harvard University.
Papers
More filters
Journal ArticleDOI
AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection.
TL;DR: The AST/ALT ratio is a dependable marker of fibrosis stage and cirrhosis in patients with chronic HCV infection.
Journal ArticleDOI
Portal vein thrombosis: a review.
TL;DR: A comprehensive description of etiologic factors and clinical aspects of portal vein thrombosis is presented and a framework for the diagnostic work-up and management of patients with PVT is provided.
Journal ArticleDOI
Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy.
TL;DR: The objective of this article is to review the available literature on the epidemiology, predisposing factors, and conditions associated with primary gallbladder cancer, and to discuss the role of prophylactic cholecystectomy in high-risk patient populations.
Journal ArticleDOI
Sickle cell hepatopathy
TL;DR: Much of the literature on sickle cell hepatopathy lacks depth, because there are few sizeable or controlled studies, and most studies provide only incomplete information regarding coexisting chronic infection with hepatitis B or C, hepatic iron deposition, and chronic biliary obstruction from choledocholithiasis.
Journal ArticleDOI
Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial
Adrian M. Di Bisceglie,Herbert L. Bonkovsky,Sanjiv Chopra,S.L. Flamm,Rajender Reddy,Norman D. Grace,Paul G. Killenberg,Christine M. Hunt,Carlo H. Tamburro,Anthony S. Tavill,Roy Ferguson,Edward L. Krawitt,Barbara F. Banner,Bruce R. Bacon +13 more
TL;DR: Although prior phlebotomy therapy does not improve the rate of sustained response to interferon retreatment, it does result in less liver injury manifested by a decrease in serum transaminase activity and a slight improvement in liver histopathology.